0001209191-23-010055.txt : 20230216
0001209191-23-010055.hdr.sgml : 20230216
20230216161605
ACCESSION NUMBER: 0001209191-23-010055
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230214
FILED AS OF DATE: 20230216
DATE AS OF CHANGE: 20230216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanna Bastiano
CENTRAL INDEX KEY: 0001829069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23638696
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-14
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001829069
Sanna Bastiano
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Cell & Genetic Therapies
Common Stock
2023-02-14
4
S
0
1902
300.29
D
60013
D
Common Stock
2023-02-14
4
S
0
279
301.11
D
59734
D
Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92).
Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22).
/s/ Christiana Stevenson, Attorney-in-Fact
2023-02-16